Kristen Donchez
Acute Care · New York, NYNPI 1922543420
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,298 of the $8,119 with a category attached, or 89.9%. 26 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2022 at $2,909 and has fallen 90.6% since, to $273 in 2025. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Nevro Corp.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$982
- Biohaven Pharmaceuticals, Inc.$981
- Collegium Pharmaceutical, Inc.$715
- Amgen$385
- plus $2K from 20 others
What the payments were for
- Consulting fees$80010%
- Food & beverage$7,29890%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $2,022 |
| Nevro Corp. | 17 | $1,043 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 97 | $982 |
| Biohaven Pharmaceuticals, Inc. | 5 | $981 |
| Collegium Pharmaceutical, Inc. | 48 | $715 |
| Amgen | 21 | $385 |
| Azurity Pharmaceuticals, Inc. | 16 | $369 |
| Scilex Pharmaceuticals Inc. | 11 | $223 |
| Hikma Pharmaceuticals USA | 11 | $192 |
| GRT US Holding, Inc. | 4 | $176 |
| Boston Scientific | 1 | $156 |
| Pfizer | 7 | $138 |
| Redhill Biopharma Inc. | 8 | $120 |
| Abbott | 2 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $95 |
| Vertex | 2 | $76 |
| Merck | 5 | $65 |
| Forte Bio-pharma LLC | 3 | $58 |
| Lundbeck LLC | 2 | $45 |
| Eisai Inc. | 3 | $41 |
| Saluda Medical Americas, Inc. | 1 | $34 |
| Almatica Pharma LLC | 2 | $27 |
| Ipsen Biopharmaceuticals, Inc | 2 | $27 |
| Medtronic | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,119 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 12 | $54,989 |
| Diclofenac Sodium | 155 | $47,832 |
| RelistorMethylnaltrexone Bromide | 18 | $41,199 |
| Xtampza ErOxycodone Myristate | 54 | $39,811 |
| Nurtec OdtRimegepant Sulfate | 18 | $30,397 |
| OxycontinOxycodone Hcl | 33 | $23,282 |
| UbrelvyUbrogepant | 21 | $21,506 |
| ZtlidoLidocaine | 38 | $20,966 |
| HorizantGabapentin Enacarbil | 27 | $14,297 |
| Lidocaine | 105 | $13,615 |
| LinzessLinaclotide | 15 | $11,669 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $7,627 |
| Fentanyl | 59 | $5,546 |
| DayvigoLemborexant | 15 | $5,328 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 217 | $4,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $982 | $41,19918 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $715 | $39,81154 claims |
| AbbVieUbrelvy, Linzess | $2,022 | $33,17436 claims |
| PfizerNurtec Odt | $138 | $30,39718 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $223 | $20,96638 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl | $192 | $10,32668 claims |
| Eisai Inc.Dayvigo | $41 | $5,32815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Julie Anne RoldanNew York$10K
- Lauren Dela CruzNew York$9K
- Tracy Valerie BertizNew York$7K
- Jennifer UllmanNew York$7K
- Sara-Jane DakroubNew York$6K
- Kathryn CiccoliniNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.